Vanguard Group’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Vanguard Group’s Portfolio NTGN Stock Details NTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-718,689	Closed	-$1.9M	–	4139
2020 Q1	$1.9M	Buy	718,689 +14,147	+2%	+$23.2K	﹤0.01%	3324
2019 Q4	$831K	Sell	704,542 -4,339	-0.6%	-$6.93K	﹤0.01%	3680
2019 Q3	$1.22M	Buy	708,881 +96,483	+16%	+$294K	﹤0.01%	3595
2019 Q2	$2.9M	Buy	612,398 +21,387	+4%	+$120K	﹤0.01%	3360
2019 Q1	$3.82M	Buy	591,011 +524,506	+789%	+$2.75M	﹤0.01%	3230
2018 Q4	$334K	Sell	66,505 -130,909	-66%	-$916K	﹤0.01%	3808
2018 Q3	$1.69M	Buy	197,414 +134,914	+216%	+$1.5M	﹤0.01%	3585
2018 Q2	$788K	Buy	+62,500	New	+$856K	﹤0.01%	3746

Vanguard Group's NTGN Position: Q2 2020 in Review

Vanguard Group sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q2 2020, closing a stake of 718,689 shares — an estimated $1.9M sold.

Vanguard Group first reported a position in NTGN in Q2 2018 and held it in 8 quarters. The position peaked at $3.82M in Q1 2019. 0 funds tracked by Wall St. Rank hold NTGN as of Q2 2020.

Vanguard Group reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Vanguard Group sold 718,689 Neon Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $1.9M.
Vanguard Group first reported a position in Neon Therapeutics, Inc. Common Stock in Q2 2018 and held it in 8 quarters.
Vanguard Group's Neon Therapeutics, Inc. Common Stock position peaked at $3.82M in Q1 2019.
0 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Vanguard Group's 13F filing for Q2 2020, filed 14 Aug 2020.